Connecticut Senate Bill SB00244

Connecticut 2015 Regular Session

• Introduced: 1/21/15
• Refer: 1/21/15

Caption

An Act Appropriating Moneys For Screening For Adrenoleukodystrophy.

Impact

If enacted, SB00244 would positively impact the health outcomes of newborns in the state by ensuring that screening for ALD becomes part of routine newborn health assessments. Early detection of ALD can lead to prompt intervention, potentially preventing severe neurological damage as well as improving the quality of life for affected individuals. The bill underscores the state's commitment to public health and emphasizes the importance of investing in preventive healthcare measures.

Summary

Bill SB00244 aims to appropriate funds for the development or validation of a reliable methodology for screening newborns for adrenoleukodystrophy (ALD). This genetic disorder affects the brain and adrenal glands, and early detection is crucial for the effective management and treatment of the condition. The bill proposes that a specific sum of money be allocated from the General Fund to the Department of Public Health for the fiscal year ending June 30, 2016, although the exact amount has not been specified in the available text.

Contention

The proposal for funding screening for adrenoleukodystrophy may face discussions surrounding budget prioritization within the broader healthcare funding landscape. Advocates for the bill argue for the necessity of early screening to improve health outcomes, while opponents may raise concerns about the allocation of limited resources within the public health budget. The bill implies a commitment to addressing rare metabolic disorders but may also spark debate over other pressing health needs within the community.